• Je něco špatně v tomto záznamu ?

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

S. Wray, E. Havrdova, DR. Snydman, DL. Arnold, JA. Cohen, AJ. Coles, HP. Hartung, KW. Selmaj, HL. Weiner, N. Daizadeh, DH. Margolin, MC. Chirieac, DAS. Compston,

. 2019 ; 25 (12) : 1605-1617. [pub] 20181005

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025627

BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and responsive to treatment. Alemtuzumab efficacy was durable over 6 years. OBJECTIVE: To evaluate infections over 6 years in alemtuzumab-treated patients. METHODS: Three randomized trials (CAMMS223, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I, and CARE-MS II) compared two courses of alemtuzumab 12 mg with SC IFNB-1a 44 μg in patients with active relapsing-remitting MS. An extension study (CAMMS03409) provided further evaluation and as-needed alemtuzumab retreatment. RESULTS: Infections occurred more frequently with alemtuzumab 12 mg than SC IFNB-1a during Years 1 (58.7% vs 41.3%) and 2 (52.6% vs 37.7%), but declined for alemtuzumab-treated patients in Years 3 (46.6%), 4 (42.8%), 5 (40.9%), and 6 (38.1%). Serious infections were uncommon (1.0%-1.9% per year). Infections were predominantly (>95%) mild to moderate and included upper respiratory tract infections, urinary tract infections, and mucocutaneous herpetic infections. Prophylactic acyclovir reduced herpetic infections. Lymphocyte counts after alemtuzumab therapy did not predict infection risk. CONCLUSION: Infections with alemtuzumab were mostly mild to moderate and decreased over time, consistent with preservation of components of protective immunity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025627
003      
CZ-PrNML
005      
20201222154014.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458518796675 $2 doi
035    __
$a (PubMed)30289355
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wray, Sibyl $u Hope Neurology MS Center, Knoxville, TN, USA.
245    10
$a Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study / $c S. Wray, E. Havrdova, DR. Snydman, DL. Arnold, JA. Cohen, AJ. Coles, HP. Hartung, KW. Selmaj, HL. Weiner, N. Daizadeh, DH. Margolin, MC. Chirieac, DAS. Compston,
520    9_
$a BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and responsive to treatment. Alemtuzumab efficacy was durable over 6 years. OBJECTIVE: To evaluate infections over 6 years in alemtuzumab-treated patients. METHODS: Three randomized trials (CAMMS223, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I, and CARE-MS II) compared two courses of alemtuzumab 12 mg with SC IFNB-1a 44 μg in patients with active relapsing-remitting MS. An extension study (CAMMS03409) provided further evaluation and as-needed alemtuzumab retreatment. RESULTS: Infections occurred more frequently with alemtuzumab 12 mg than SC IFNB-1a during Years 1 (58.7% vs 41.3%) and 2 (52.6% vs 37.7%), but declined for alemtuzumab-treated patients in Years 3 (46.6%), 4 (42.8%), 5 (40.9%), and 6 (38.1%). Serious infections were uncommon (1.0%-1.9% per year). Infections were predominantly (>95%) mild to moderate and included upper respiratory tract infections, urinary tract infections, and mucocutaneous herpetic infections. Prophylactic acyclovir reduced herpetic infections. Lymphocyte counts after alemtuzumab therapy did not predict infection risk. CONCLUSION: Infections with alemtuzumab were mostly mild to moderate and decreased over time, consistent with preservation of components of protective immunity.
650    _2
$a dospělí $7 D000328
650    _2
$a alemtuzumab $x škodlivé účinky $x terapeutické užití $7 D000074323
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $7 D061067
650    _2
$a náchylnost k nemoci $7 D004198
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a infekce $7 D007239
650    _2
$a interferon beta 1a $x aplikace a dávkování $7 D000068556
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    _2
$a recidiva $7 D012008
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Havrdova, Eva $u MS Center, Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Snydman, David R $u Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA.
700    1_
$a Arnold, Douglas L $u Montréal Neurological Institute, McGill University, Montréal, QC, Canada.
700    1_
$a Cohen, Jeffrey A $u Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Coles, Alasdair J $u University of Cambridge School of Clinical Medicine, Cambridge, UK.
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
700    1_
$a Selmaj, Krzysztof W $u Medical University of Łódź, Łódź, Poland.
700    1_
$a Weiner, Howard L $u The Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Daizadeh, Nadia $u Sanofi, Cambridge, MA, USA.
700    1_
$a Margolin, David H $u Sanofi, Cambridge, MA, USA.
700    1_
$a Chirieac, Madalina C $u Sanofi, Cambridge, MA, USA.
700    1_
$a Compston, D Alastair S $u University of Cambridge School of Clinical Medicine, Cambridge, UK.
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 25, č. 12 (2019), s. 1605-1617
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30289355 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154010 $b ABA008
999    __
$a ok $b bmc $g 1599772 $s 1116313
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 12 $d 1605-1617 $e 20181005 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace